Vol. 19 No. 4-2 (2015): Cell Technologies in Cardiology (Special Issue)
REVIEWS

Application of induced pluripotent stem cell technology to model long QT syndrome

PDF (Русский)
  • A. Vyalkova,
  • E. Dement'eva,
  • S. Medvedev,
  • E. Pokushalov,
  • S. Zakiyan
A. Vyalkova
The Federal Research Center Institute of Cytology and Genetics, The Siberian Branch of the Russian Federation Academy of Sciences, 10 Lavrentieva Avenue, 630090 Novosibirsk, Russian Federation; Academician Ye. Meshalkin Novosibirsk Research Institute of Circulation Pathology, Ministry of Health Care of Russian Federation, 15 Rechkunovskaya St., 630055 Novosibirsk, Russian Federation; Institute of Chemical Biology and Fundamental Medicine, The Siberian Branch of the Russian Federation Academy of Sciences, 8 Lavrentieva Avenue, 630090 Novosibirsk, Russian Federation
E. Dement'eva
The Federal Research Center Institute of Cytology and Genetics, The Siberian Branch of the Russian Federation Academy of Sciences, 10 Lavrentieva Avenue, 630090 Novosibirsk, Russian Federation; Academician Ye. Meshalkin Novosibirsk Research Institute of Circulation Pathology, Ministry of Health Care of Russian Federation, 15 Rechkunovskaya St., 630055 Novosibirsk, Russian Federation; Institute of Chemical Biology and Fundamental Medicine, The Siberian Branch of the Russian Federation Academy of Sciences, 8 Lavrentieva Avenue, 630090 Novosibirsk, Russian Federation
S. Medvedev
The Federal Research Center Institute of Cytology and Genetics, The Siberian Branch of the Russian Federation Academy of Sciences, 10 Lavrentieva Avenue, 630090 Novosibirsk, Russian Federation; Academician Ye. Meshalkin Novosibirsk Research Institute of Circulation Pathology, Ministry of Health Care of Russian Federation, 15 Rechkunovskaya St., 630055 Novosibirsk, Russian Federation; Institute of Chemical Biology and Fundamental Medicine, The Siberian Branch of the Russian Federation Academy of Sciences, 8 Lavrentieva Avenue, 630090 Novosibirsk, Russian Federation; Novosibirsk National Research State University, 2 Pirogova St., 630090 Novosibirsk, Russian Federation
E. Pokushalov
Academician Ye. Meshalkin Novosibirsk Research Institute of Circulation Pathology, Ministry of Health Care of Russian Federation, 15 Rechkunovskaya St., 630055 Novosibirsk, Russian Federation
S. Zakiyan
The Federal Research Center Institute of Cytology and Genetics, The Siberian Branch of the Russian Federation Academy of Sciences, 10 Lavrentieva Avenue, 630090 Novosibirsk, Russian Federation; Academician Ye. Meshalkin Novosibirsk Research Institute of Circulation Pathology, Ministry of Health Care of Russian Federation, 15 Rechkunovskaya St., 630055 Novosibirsk, Russian Federation; Institute of Chemical Biology and Fundamental Medicine, The Siberian Branch of the Russian Federation Academy of Sciences, 8 Lavrentieva Avenue, 630090 Novosibirsk, Russian Federation; Novosibirsk National Research State University, 2 Pirogova St., 630090 Novosibirsk, Russian Federation
DOI: https://doi.org/10.21688/1681-3472-2015-4-2-85-94

Published 2016-01-14

Keywords

  • long QT syndrome,
  • induced pluripotent stem cells,
  • cardiomyocytes

How to Cite

Vyalkova, A., Dement’eva, E., Medvedev, S., Pokushalov, E., & Zakiyan, S. (2016). Application of induced pluripotent stem cell technology to model long QT syndrome. Patologiya Krovoobrashcheniya I Kardiokhirurgiya, 19(4-2), 85–94. https://doi.org/10.21688/1681-3472-2015-4-2-85-94

Copyright (c) 2016 Vyalkova A.V., Dement'eva E.V., Medvedev S.P., Pokushalov E.A., Zakiyan S.M.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Long QT syndrome (LQTS) is an arrhythmic disease associated with an increased risk of ventricular tachycardia and sudden death. Despite numerous studies that have been performed in last years, the disease is still poorly understood and existing therapy methods are not highly effective. One of the main problems is the absence of good LQTS models. Technology based on induced pluripotent stem cells (iPSCs) opens a new era in human genetic disease modeling including inherited cardiovascular diseases. Capacity of iPSCs to be differentiated into functional cardiomyocytes allows iPSC using to study molecular mechanisms of cardiovascular diseases and to search for new drugs for their therapy. In this review, application of the technology in LQTS modeling and the progress that has been made in the area will be considered in detail.

PDF (Русский)

References

  1. Crotti L., Celano G., Dagradi F., Schwartz P.J. Congenital long QT syndrome // Orphanet. J. Rare Dis. 2008. Vol. 3. P. 18.
  2. Schwartz P.J., Stramba-Badiale M., Crotti L., Pedrazzini M., Besana A., Bosi G., Gabbarini F., Goulene K., Insolia R., Mannarino S., Mosca F., Nespoli L., Rimini A., Rosati E., Salice P., Spazzolini C. Prevalence of the congenital long-QT syndrome // Circulation. 2009. Vol. 120. № 18. P. 1761–7.
  3. Roden D.M. Acquired long QT syndromes and the risk of proarrhythmia // J. Cardiovasc. Electrophysiol. 2000. Vol. 11. № 8. P. 938–40.
  4. Hedley P.L., Jorgensen P., Schlamowitz S., Wangari R., Moolman-Smook J., Brink P.A., Kanters J.K., Corfield V.A., Christiansen M. The genetic basis of long QT and short QT syndromes: a mutation update // Hum. Mutat. 2009. Vol. 30. № 11. P. 1486–511.
  5. Boczek N.J., Best J.M., Tester D.J., Giudicessi J.R., Middha S., Evans J.M., Kamp T.J., Ackerman M.J. Exome sequencing and systems biology converge to identify novel mutations in the L-type calcium channel, CACNA1C, linked to autosomal dominant long QT syndrome // Circ. Cardiovasc. Genet. 2013. Vol. 6. № 3. P. 279–89.
  6. Salama G, London B. Mouse models of long QT syndrome // J. Physiol. 2007. Vol. 578. Pt. 1. P. 43–53.
  7. Hoekstra M., Mummery C.L., Wilde A.A., Bezzina C.R., Verkerk A.O. Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias // Front. Physiol. 2012. Vol. 3. P. 346.
  8. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors // Cell. 2006. Vol. 126. № 4. P. 663–76.
  9. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., Nie J., Jonsdottir G.A., Ruotti V., Stewart R., Slukvin I.I., Thomson J.A. Induced pluripotent stem cell lines derived from human somatic cells // Science. 2007. Vol. 318. № 5858. P. 1917–20.
  10. Mordwinkin N.M., Burridge P.W., Wu J.C. A review of human pluripotent stem cell-derived cardiomyocytes for high-throughput drug discovery, cardiotoxicity screening, and publication standards // J. Cardiovasc. Transl. Res. 2013. Vol. 6. № 1. P. 22–30.
  11. Shimizu W., Horie M., Ohno S., Takenaka K., Yamaguchi M., Shimizu M., Washizuka T., Aizawa Y., Nakamura K., Ohe T., Aiba T., Miyamoto Y., Yoshimasa Y., Towbin J.A., Priori S.G., Kamakura S. Mutation site-specific differences in arrhythmic risk and sensitivity to sympathetic stimulation in the LQT1 form of congenital long QT syndrome: multicenter study in Japan // J. Am. Coll. Cardiol. 2004. Vol. 44. № 1. P. 117–25.
  12. Moss A.J., Shimizu W., Wilde A.A., Towbin J.A., Zareba W., Robinson J.L., Qi M., Vincent G.M., Ackerman M.J., Kaufman E.S., Hofman N., Seth R., Kamakura S., Miyamoto Y., Goldenberg I., Andrews M.L., McNitt S. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene // Circulation. 2007. Vol. 115. № 19. P. 2481–9.
  13. Priori S.G., Napolitano C., Schwartz P.J. Low penetrance in the long-QT syndrome: clinical impact // Circulation. 1999. Vol. 99. № 4. P. 529–33.
  14. Moss A.J., Zareba W., Kaufman E.S., Gartman E., Peterson D.R., Benhorin J., Towbin J.A., Keating M.T., Priori S.G., Schwartz P.J., Vincent G.M., Robinson J.L., Andrews M.L., Feng C., Hall W.J., Medina A., Zhang L., Wang Z. Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel // Circulation. 2002. Vol. 105. № 7. P. 794–9.
  15. Scicluna B.P., Wilde A.A., Bezzina C.R. The primary arrhythmia syndromes: same mutation, different manifestations. Are we starting to understand why? // J. Cardiovasc. Electrophysiol. 2008. Vol. 19. № 4. P. 445–52.
  16. Moretti A., Bellin M., Welling A., Jung C.B., Lam J.T., Bott-Flügel L., Dorn T., Goedel A., Höhnke C., Hofmann F., Seyfarth M., Sinnecker D., Schömig A., Laugwitz K.L. Patient-specific induced pluripotent stem-cell models for long-QT syndrome // N. Engl. J. Med. 2010. Vol. 363. № 15. P. 1397–409.
  17. Egashira T., Yuasa S., Suzuki T., Yae K., Aizawa Y., Yamakawa H., Murata M., Miyoshi S., Kamiya K., Fukuda K. Disease characterization using LQTS-specific induced pluripotent stem cells // Cardiovasc. Res. 2012. Vol. 95. № 4. P. 419–29.
  18. Itzhaki I., Maizels L., Huber I., Zwi-Dantsis L., Caspi O., Winterstern A., Feldman O., Gepstein A., Arbel G., Hammerman H., Boulos M., Gepstein L. Modelling the long QT syndrome with induced pluripotent stem cells // Nature. 2011. Vol. 471. № 7337. P. 225–9.
  19. Lahti A.L., Kujala V.J., Chapman H., Koivisto A.P., Pekkanen-Mattila M., Kerkelä E., Hyttinen J., Kontula K., Swan H., Conklin B.R., Yamanaka S., Silvennoinen O., Aalto-Setälä K. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture // Dis. Model. Mech. 2012. Vol. 5. № 2. P. 220–30.
  20. Ma D., Wei H., Zhao Y., Lu J., Li G., Sahib N.B., Tan T.H., Wong K.Y., Shim W., Wong P., Cook S.A., Liew R. Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells // Int. J. Cardiol. 2013. Vol. 168. № 6. P. 5277–86.
  21. Terrenoire C., Wang K., Tung K.W., Chung W.K., Pass R.H., Lu J.T., Jean J.C., Omari A., Sampson K.J., Kotton D.N., Keller G., Kass R.S. Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics // J. Gen. Physiol. 2013. Vol. 141. № 1. P. 61–72.
  22. Yazawa M., Hsueh B., Jia X., Pasca A.M., Bernstein J.A., Hallmayer J., Dolmetsch R.E. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome // Nature. 2011. Vol. 471. № 7337. P. 230–4.
  23. Splawski I., Timothy K.W., Sharpe L.M., Decher N., Kumar P., Bloise R., Napolitano C., Schwartz P.J., Joseph R.M., Condouris K., Tager-Flusberg H., Priori S.G., Sanguinetti M.C., Keating M.T. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism // Cell. 2004. Vol. 119. № 1. P. 19–31.
  24. Ma D., Wei H., Lu J., Huang D., Liu Z., Loh L.J., Islam O., Liew R., Shim W., Cook S.A. Characterization of a novel KCNQ1 mutation for type 1 long QT syndrome and assessment of the therapeutic potential of a novel IKs activator using patient-specific induced pluripotent stem cell-derived cardiomyocyte // Stem Cell Res. Ther. 2015. Vol. 6. P. 39.
  25. Matsa E., Rajamohan D., Dick E., Young L., Mellor I., Staniforth A., Denning C. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation // Eur. Heart J. 2011. Vol. 32. № 8. P. 952–62.
  26. Liang P., Lan F., Lee A.S., Gong T., Sanchez-Freire V., Wang Y., Diecke S., Sallam K., Knowles J.W., Wang P.J., Nguyen P.K., Bers D.M., Robbins R.C., Wu J.C. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity // Circulation. 2013. Vol. 127. № 16. P. 1677–91.
  27. Bellin M., Casini S., Davis R.P., D'Aniello C., Haas J., Ward-van Oostwaard D., Tertoolen L.G., Jung C.B., Elliott D.A., Welling A., Laugwitz K.L., Moretti A., Mummery C.L. Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome // EMBO J. 2013. Vol. 32. № 24. P. 3161–75.
  28. Gouas L., Nicaud V., Berthet M., Forhan A., Tiret L., Balkau B., Guicheney P. Association of KCNQ1, KCNE1, KCNH2 and SCN5A polymorphisms with QTc interval length in a healthy population // Eur. J. Hum. Genet. 2005. Vol. 13. № 11. P. 1213–22.
  29. Pfeufer A., Jalilzadeh S., Perz S., Mueller J.C., Hinterseer M., Illig T., Akyol M., Huth C., Schöpfer-Wendels A., Kuch B., Steinbeck G., Holle R., Näbauer M., Wichmann H.E., Meitinger T., Kääb S. Common variants in myocardial ion channel genes modify the QT interval in the general population: results from the KORA study // Circ. Res. 2005. Vol. 96. № 6. P. 693–701.
  30. Mank-Seymour A.R., Richmond J.L., Wood L.S., Reynolds J.M., Fan Y.T., Warnes G.R., Milos P.M., Thompson J.F. Association of torsades de pointes with novel and known single nucleotide polymorphisms in long QT syndrome genes // Am. Heart J. 2006. P. 152. № 6. P. 1116–22.
  31. Newton-Cheh C., Guo C.Y., Larson M.G., Musone S.L., Surti A., Camargo A.L., Drake J.A., Benjamin E.J., Levy D., D'Agostino R.B.Sr, Hirschhorn J.N., O'donnell C.J. Common genetic variation in KCNH2 is associated with QT interval duration: the Framingham Heart Study // Circulation. 2007. Vol. 116. № 10. P. 1128–36.
  32. Marjamaa A., Newton-Cheh C., Porthan K., Reunanen A., Lahermo P., Väänänen H., Jula A., Karanko H., Swan H., Toivonen L., Nieminen M.S., Viitasalo M., Peltonen L., Oikarinen L., Palotie A., Kontula K, Salomaa V. Common candidate gene variants are associated with QT interval duration in the general population // J. Intern. Med. 2009. Vol. 265. № 4. P. 448–58.
  33. Chen L., Zhang W., Fang C., et al. Polymorphism H558R in the human cardiac sodium channel SCN5A gene is associated with atrial fibrillation // J. Int. Med. Res. 2011. Vol. 39. № 5. P. 1908–16.
  34. Matsa E., Dixon J.E., Medway C., Georgiou O., Patel M.J., Morgan K., Kemp P.J., Staniforth A., Mellor I., Denning C. Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes // Eur. Heart J. 2014. Vol. 35. № 16. P. 1078–87.
  35. Maherali N., Hochedlinger K. Guidelines and techniques for the generation of induced pluripotent stem cells // Cell Stem Cell. 2008. Vol. 3. № 6. P. 595–605.
  36. Gore A., Li Z., Fung H.L., Young J.E, Agarwal S., Antosiewicz-Bourget J., Canto I., Giorgetti A., Israel M. A., Kiskinis E., Lee J.H., Loh Y.H., Manos P.D., Montserrat N., Panopoulos A.D., Ruiz S., Wilbert M.L., Yu J., Kirkness E.F., Belmonte J.C.I., Rossi D.J., Thomson J.A., Eggan K., Daley G.Q., Goldstein L.S.B., Zhang K. Somatic coding mutations in human induced pluripotent stem cells // Nature. 2011. Vol. 471. № 7336. P. 63–7.
  37. Medvedev S.P., Grigor'eva E.V., Shevchenko A.I., Malakhova A.A., Dementyeva E.V., Shilov A.A., Pokushalov E.A., Zaidman A.M., Aleksandrova M.A., Plotnikov E.Y., Sukhikh G.T., Zakian S.M. Human induced pluripotent stem cells derived from fetal neural stem cells successfully undergo directed differentiation into cartilage // Stem Cells Dev. 2011. Vol. 20. № 6. P. 1099–112.
  38. Yu J., Hu K., Smuga-Otto K., Tian S., Stewart R., Slukvin I.I., Thomson J.A. Human induced pluripotent stem cells free of vector and transgene sequences // Science. 2009. Vol. 324. № 5928. P. 797–801.
  39. Zhou W., Freed C.R. Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells // Stem Cells. 2009. Vol. 27. № 11. P. 2667–74.
  40. Kim K., Doi A., Wen B., Ng K., Zhao R., Cahan P., Kim J., Aryee M.J., Ji H., Ehrlich L., Yabuuchi A., Takeuchi A., Cunniff K.C., Hongguang H., Mckinney-Freeman S., Naveiras O., Yoon T.J., Irizarry R.A., Jung N., Seita J., Hanna J., Murakami P., Jaenisch R., Weissleder R., Orkin S.H., Weissman I.L., Feinberg A.P., Daley G.Q. Epigenetic memory in induced pluripotent stem cells // Nature. 2010. Vol. 467. № 7313. P. 285–90.
  41. Polo J.M., Liu S., Figueroa M.E., Kulalert W., Eminli S., Tan K.Y., Apostolou E., Stadtfeld M., Li Y., Shioda T., Natesan S., Wagers A.J., Melnick A., Evans T., Hochedlinger K. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells // Nat. Biotechnol. 2010. Vol. 28. № 8. P. 848–55.
  42. Kim K., Zhao R., Doi A., Ng K., Unternaehrer J., Cahan P., Huo H., Loh Y.H., Aryee M.J., Lensch M.W., Li H., Collins J.J., Feinberg A.P., Daley G.Q. Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells // Nat. Biotechnol. 2011. Vol. 29. № 12. P. 1117–9.
  43. Chan Y.C., Ting S., Lee Y.K., Ng K.M., Zhang J., Chen Z., Siu C.W., Oh S.K., Tse H.F. Electrical stimulation promotes maturation of cardiomyocytes derived from human embryonic stem cells // J. Cardiovasc. Transl. Res. 2013. Vol. 6. № 6. P. 989–99.
  44. Ivashchenko C.Y., Pipes G.C., Lozinskaya I.M., Lin Z., Xiaoping X., Needle S., Grygielko E.T., Hu E., Toomey J.R., Lepore J.J., Willette R.N. Human-induced pluripotent stem cell-derived cardiomyocytes exhibit temporal changes in phenotype // Am. J. Physiol. Heart. Circ. Physiol. 2013. Vol. 305. № 6. P. H913–22.
  45. Mihic A., Li J., Miyagi Y., Gagliardi M., Li S.H., Zu J., Weisel R.D., Keller G., Li R.K. The effect of cyclic stretch on maturation and 3D tissue formation of human embryonic stem cell-derived cardiomyocytes // Biomaterials. 2014. Vol. 35. № 9. P. 2798–808.
  46. Ding Q., Lee Y.K., Schaefer E.A., et al. A TALEN genome-editing system for generating human stem cell-based disease models // Cell Stem Cell. 2013. Vol. 12. № 2. P. 238–51.
  47. Ding Q., Regan S.N., Xia Y., Oostrom L.A., Cowan C.A., Musunuru K. Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs // Cell Stem Cell. 2013. Vol. 12. № 4. P. 393–4.
  48. Kadota S., Minami I., Morone N., Heuser J.E., Agladze K., Nakatsuji N. Development of a reentrant arrhythmia model in human pluripotent stem cell-derived cardiac cell sheets // Eur. Heart J. 2013. Vol. 34. № 15. P. 1147–56.
  49. Sinnecker D., Goedel A., Dorn T., Dirschinger R.J., Moretti A., Laugwitz K.L. Modeling long-QT syndromes with iPS cells // J. Cardiovasc. Transl. Res. 2013. Vol. 6. № 1. P. 31–6.
  50. Okata S., Yuasa S., Yamane T., Furukawa T., Fukuda K. The generation of induced pluripotent stem cells from a patient with KCNH2 G603D, without LQT2 disease associated symptom // J. Med. Dent. Sci. 2013. Vol. 60. № 1. P. 17–22.